Logo for the University of Illinois at Chicago
    • Login
    View Item 
    •   INDIGO Home
    • Pharmacy, College of
    • Pharmacy Practice, Department of
    • Publications - Pharmacy Practice
    • View Item
    •   INDIGO Home
    • Pharmacy, College of
    • Pharmacy Practice, Department of
    • Publications - Pharmacy Practice
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia

    Thumbnail
    View/Open
    Main article (145.2Kb)
    Date
    2015
    Author
    Bonaccorso, S.
    Sodhi, MS
    Li, S.
    Bobo, WV
    Chen, Y.
    Tumuklu, M.
    Publisher
    Wiley Periodicals Inc.
    Metadata
    Show full item record
    Abstract
    Objectives: We tested the hypothesis that a common functional variant in brain-derived neurotrophic factor (BDNF), Val66Met, which has been shown to be associated with increased body mass index (BMI) in schizophrenia (SCZ) and schizoaffective disorder (SAD), is also associated with antipsychotic-induced weight gain in bipolar disorder (BPD). Association of Val66Met with other metabolic measures, including high- and low-density cholesterol, triglycerides, total cholesterol, fasting blood glucose, and hemoglobin A1c, was also tested. Methods: This was a 12-month, prospective, randomized trial of two atypical antipsychotic drugs (APDs) with moderate (risperidone) or high (olanzapine) risk to cause weight gain. Subjects were diagnosed as having BPD (n = 90) and SCZ or SAD (n = 76). Results: BMI was significantly greater in all diagnoses for Met66 allele carriers at six months (p = 0.01). Met66 carriers with BPD showed a greater increase in the triglycerides/high-density (HDL) cholesterol ratio (p = 0.01), a key marker for metabolic syndrome related to insulin resistance, and log-triglycerides (p = 0.04), after three or six months of treatment. Met66 carriers had the greatest increase in log-triglycerides (p = 0.03) and triglycerides/HDL cholesterol ratio after three months of treatment with risperidone (p = 0.003), and the highest BMI at six months (p = 0.01). Conclusions: The positive association of BNDF Val66Met with high BMI values replicates previous findings in patients with SCZ and indicates the BDNF Val66Met genotype as a potential risk factor for obesity and insulin resistance measures in patients with BPD receiving antipsychotics as well.
    Subject
    antipsychotic drugs
    brain-derived neurotrophic factor (BDNF) Val66Met
    bipolar disorder
    body mass index
    glucose
    lipids
    schizophrenia
    Type
    Article
    Date available in INDIGO
    2016-01-28T23:37:16Z
    URI
    http://hdl.handle.net/10027/20070
    Collections
    • Publications - Pharmacy Practice

    DSpace software copyright © 2002-2015  DuraSpace
    Contact Us | Send Feedback | Privacy Statement
    Theme by 
    Atmire NV

    Browse

    All of INDIGOCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    DSpace software copyright © 2002-2015  DuraSpace
    Contact Us | Send Feedback | Privacy Statement
    Theme by 
    Atmire NV